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PODIUM SESSION I: ADHERENCE/COMPLIANCE STUDIES
AC1
PERSISTENCE WITH ANTIHYPERTENSIVE DRUG CLASSES; INFLUENCE 
OF METHOD ASSUMPTIONS
Nguyen NH, Vegter S, Visser ST, Postma MJ, de Jong-van den Berg LTW, Boersma C
University of Groningen, Groningen, The Netherlands
OBJECTIVES: Inaccurate use of chronic medication is a serious problem for patients 
and health care professionals due to lower effectiveness of treatment. Non-persistence 
is likely to result in worsening of disease prognosis and increasing health care expen-
ditures. The aim of the study was to investigate persistence with antihypertensive 
drugs. METHODS: A cohort study was conducted based on Dutch pharmacy dispens-
ing records from IADB.nl. Enrolled were patients who initiated antihypertensive drugs 
in the period from 1st of January 1999 to 30th of June 2007. Patients with previous 
use of antihypertensive drugs 365 days prior to start, total supply 30 days, and 
patients aged 18 years were excluded. Antihypertensive drug classes included were 
diuretics, beta-blockers (BBs), calcium-channel blockers (CCBs), ACE-inhibitors 
(ACE), and angiotensin receptor blockers (ARBs). Persistence was measured by com-
bining the proportion of days covered (PDC) of 80% and a gap period of 30 days 
(hybrid method). Both the PDC and gap period were varied in the sensitivity analysis. 
Cox proportional hazard analysis was conducted to calculate the unadjusted and 
adjusted (for age, gender, combi/mono therapy, and year of initiation) hazard ratios 
(HR) and 95% conﬁdence intervals (95%CI) for the different antihypertensive drug 
classes. RESULTS: A total of 55,010 patients initiated antihypertensive drugs. Cox 
regression analysis showed statistically signiﬁcant better persistence with ARBs as 
compared to other antihypertensives with adjusted HR of non-persistence of 1.33 
(95%CI: 1.24–1.42), 1.76 (95%CI: 1.65–1.87), 1.98 (95%CI: 1.86–2.12), and 2.36 
(95%CI: 2.19–2.53) for ACE, BBs, diuretics and CCBs, respectively. Variation in PDC 
and gap period had statistically signiﬁcant inﬂuence on the survival, but did not inﬂu-
ence the relative persistence of ARBs versus other antihypertensive drugs. CONCLU-
SIONS: Chronic users of antihypertensives are estimated to be most persistent with 
ARBs. Further results will be presented on the predictive value of current persistence 
on future adherence, as well as cost implications.
AC2
SUCCESS FACTORS IMPROVING PATIENT COMPLIANCE BEHAVIOUR—
EMPIRICAL FINDINGS FROM EUROPE
Schäfer C
Johannes Gutenberg-University of Mainz, Mainz, Germany
OBJECTIVES: The current discussion in health economics is focused on potential 
efﬁciency reserves in patient compliance behaviour. Yet there is little empirical evi-
dence regarding the impact of special control variables on patient behaviour in Europe. 
We analyze which factors positively inﬂuence patient compliance decision. METHODS: 
We built a simple structural equation model reﬂecting the trade-off between perceived 
side effects and patient compliance behaviour. This behavioural model is applied to 
clinical trial data. In the analysis, compliance is deﬁned as a dichotomous variable 
enhancing the discriminatory power of our results. Furthermore, our data allows the 
comparison of patient compliance behaviour between different subgroups, e.g. insur-
ance status. RESULTS: A total of 1035 patients with a primary diagnosis of hyperten-
sion were included in the study utilizing a clinical trial in Germany between 2007 and 
2008. The strongest inﬂuence on a patient’s intended compliance is the degree of per-
ceived therapy control (path coefﬁcient: 0.48; p  0.01) followed by coping with 
therapy barriers (pc: 0.35; p  0.05), physician-patient-communication (pc: 0.33; p  
0.05) and social environment (pc: 0.28, p  0.01). Moreover, general patient compli-
ance behaviour is highly dependent on health insurance status. CONCLUSIONS: This 
study shows tangible starting points on how patients can be encouraged to take a 
more active role in their health care in order to optimize outcome and minimize risk. 
By reaching an exceptionally high explanatory power, our model identiﬁes compre-
hensive strategies regarding the improvement of patient compliance. A combination 
of cognitive, behavioural, and affective components is signiﬁcantly more effective than 
single-focused strategies both in the complete sample as well as in any of the here 
considered subgroups.
AC3
NON-ADHERENCE IN OUTPATIENT THROMBOSIS PROPHYLAXIS 
AFTER MAJOR ORTHOPAEDIC SURGERY
Wilke T
University of Wismar, Wismar, Germany
OBJECTIVES: In current guidelines, extended thromboprophylaxis after a hip and 
knee replacement surgery is recommended. Based on the largest empirical survey to 
date dealing with the question of LMWH (low molecular weight heparins) non-
 adherence (NA), this study aims to deal with two main topics: (1) the study assesses 
whether there is any quantitative relevance of outpatient thromboprophylaxis in 
Germany; and (2) the degree of any non-adherence of patients in LMWH outpatient 
prophylaxis is assessed. METHODS: For data collection we performed structured 
telephone interviews with 1415 hip and knee replacement patients. Non-adherence 
was determined by syringe count and by indirect and direct questions to patients. All 
in all, 6 different non-adherence indicators based on patient interviews were deﬁned. 
For multivariate analysis of factors explaining patients`non-adherence (based on 
WHO recommendations), we estimated 3 different logistic regressions models. 
RESULTS: For about 90% of patients, outpatient prophylaxis is of relevance in 
Germany. Non-adherence rates in LMWH outpatient prophylaxis range between 13% 
and 21% depending on the indicator used for measurement. Non-adherent patients 
miss between 38–53% of all their outpatient LMWH injections. If patients attend an 
outpatient rehabilitation program, the probability of their non-adherence increases 
signiﬁcantly. Moreover, the non-adherence probability increases with each additional 
day of bridging (days between acute hospitalization and start of rehabilitation). Non-
adherence is lower in patients who fear any thrombosis or who believe that antithrom-
botic drugs are the most important measure in thromboprophylaxis. CONCLUSIONS: 
Non-adherence in outpatient thromboprophylaxis seems to be a serious challenge. It 
can also be assumed that outpatient prophylaxis in other countries is at least as 
important as it is in Germany, for the simple reason that most other countries do not 
have a comprehensive network of inpatient rehabilitation clinics.
AC4
A RETROSPECTIVE COHORT STUDY OF MEDICATION ADHERENCE TO 
TREATMENT OF OSTEOPOROSIS IN A SWEDISH POPULATION
Landfeldt E1, Borgström F1, Robbins S2, Ström O1
1i3 Innovus, Stockholm, Sweden, 2Amgen Europe GmbH, Zug, Switzerland
OBJECTIVES: Medication adherence is a problem in the treatment of osteoporosis. 
The aim of this study was to explore osteoporosis medication adherence in a Swedish 
population. METHODS: The study was based on the Swedish Prescription Register 
and included all patients (50 years) who ﬁlled prescriptions for one or several osteo-
porosis treatments (alendronate, risedronate, etidronate, strontium, and/or raloxifene) 
between 2005 and 2008. A washout-period of 5 months was used to include treat-
ment-naïve patients. Inpatient care data and death dates were extracted from the 
National Patient Register and the Causes-of-Death Register. Patients with secondary 
osteoporosis were excluded via ICD-10 codes. Medication Possession Ratio (MPR) 
was used to measure compliance in persistent patients (switching allowed). Treatment 
persistence and its determinants were investigated using failure time analysis with a 
permissible treatment gap of 2 months. RESULTS: The ﬁnal study population included 
53,364 patients receiving treatment for osteoporosis, with a mean age of 71 years. 
Average follow-up of was 314 days (max 1126). A total of 91%, 74%, 62%, 46%, 
29%, and 16% remained on treatment (switching allowed) after 1 month, 3 months, 
6 months, 1 year, 2 years, and 3 years, respectively. Average time on treatment was 
estimated at 461 days. Average MPR in persistent patients was 94.19% (CI95% 94.12–
94.26). Weekly regimens were associated with better persistence than daily regimens 
(HR  0.554, p  0.001). Patients with prevalent co-morbidities were more likely to 
terminate treatment (HR  1.12, p  0.001) and women had better persistence than 
men (HR  0.866, p  0.001). CONCLUSIONS: Less than half of the patients included 
in the study remained on treatment after 1 year and only 16% after 3 years. Dosing 
regimens and prevalent comorbidities were important factors for the estimated dis-
continuation rates. Osteoporosis medication persistence in Sweden is far from optimal 
and consequently a serious problem in the medical management of osteoporotic 
patients.
PODIUM SESSION I: CANCER STUDIES I
CN1
HOW MUCH DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF 
LIFE MATTER IN COST-EFFECTIVENESS ANALYSIS? A COMPARISON  
OF COST/LIFE YEAR AND COST/QALY ESTIMATES FOR CANCER 
INTERVENTIONS
Greenberg D, Cohen JT, Fang C, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: We investigated the extent to which adjusting for health-related quality 
of life (HRQoL) alters incremental cost per life year ratios for cancer interventions 
and the implications for reimbursement decisions. METHODS: We identiﬁed all 
studies pertaining to cancer in the Tufts cost-effectiveness analysis registry (www.
cearegistry.org) published through 2006 in which both a cost/QALY and a cost/life-
year gained were reported. We calculated the spearman correlation to assess the 
ordinal relationship between these ratios. We used $50,000 and $100,000 per QALY/
life-year thresholds to identify interventions where the use of cost/QALY ratio might 
yield different resource allocation than the use of cost/life-year. RESULTS: Cost/
QALY and cost/life-year rations were reported for 154 interventions. In 7 of these 
ratio pairs (5%), the intervention was either dominant or dominated. Because no ratios 
could be calculated, we excluded these ratio pairs from our analysis. The median 
cost/QALY and cost/life year ratios for the sample of identical interventions were 
$26,700/QALY and $24,700/ life year. The rank order correlation between these two 
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